groups: very low risk (¼pT3a disease, pure transitional histology and negative STSM), low risk (¼pT3a disease, non-pure transitional histology and negative STSM), intermediate risk (pT4 disease, negative STSM and any histology), and high risk (all patients with positive STSM).
INTRODUCTION AND OBJECTIVES:
The role of cancerrelated inflammation pathways as proxy of aggressiveness is well known in several cancers. Preoperative anemia and thrombocytosis are known to be associated with aggressive disease features in bladder cancer (BCa) . Accordingly, we hypothesized that a single variable including hemoglobin (HB) and platelet count (PLT) (HB to PLT ratio [HPR] ) could consider the synergic effect of both factors. We aim to evaluate if HPR can represent a predictor of cancer specific mortality (CSM) or overall mortality (OM) in patients treated with radical cystectomy (RC) for BCa METHODS: We evaluated 963 patients diagnosed with BCa and treated with RC between 1987 and 2015 at our institution. Routine laboratory measurements were performed preoperatively the day before surgery. Univariate and multivariable Cox proportional hazards regression analyses were used to predict CSM and OM. Covariates included age at surgery, gender, pathological T stage, pathological N stage, preoperative hydronephrosis, ASA score, surgical margins, lymph vascular invasion and neoadjuvant chemotherapy RESULTS: Median age was 69 years (IQR 62-75 years). HB was measured as g/L while PLT was measured as 10^9 L-1. Preoperative median HPR was 0.55 (IQR 0.41-0.70 ). Overall, 304, 129 and 540 patients were recorded with lymph node metastases, positive surgical margins and pT3-4 stage, respectively. CSM was observed in 385 (39%) patients, whereas OM was observed in 148 patients (48%). Median follow-up was 58 months . Patients with a HPR lower than 0.55 had adverse pathological characteristics, such as high grade (P < 0.001), advanced T stage (P < 0.001) and lymph node invasion (P < 0.001). At univariate analysis HPR higher than 0.55 was associated with lower risk of CSM and OM (respectively HR 0.224 and 0.291; CI 0.131-0.381 and 0.291-0.468; all p <0.001). At multivariate analysis preoperative HPR was associated with lower risk to incur CSM and OM (respectively HR 0.134 and 0.162; CI 0.05-0.37 and 0.07-0.41; all p <0.001). Other predictors of CSM were N stage and positive margins while neoadjuvant chemotherapy was inversely associated to CSM. Other predictors of OM were ASA score, age at surgery and N stage while neoadjuvant chemotherapy was inversely linked to OM CONCLUSIONS: Despite the well known role of anemia and thrombocytosis as predictors of survival in BCa, HPR (that include both factors) should be considered as a powerful prognostic marker, expression of inflammation and of the disease aggressiveness. However further investigations are needed to fully understand the impact of inflammation in BCa Source of Funding: none METHODS: we evaluated 1,081 contemporary patients with clinically non metastatic BCa with available follow-up and recurrence site information, treated with RC and pelvic lymph node dissection (PLND) at a single tertiary care referral center (testing cohort) between 1990 and 2013. Findings from the first dataset were subsequently evaluated in an independent cohort composed of 433 patients who were treated with RC and PLND for clinically nonmetastatic BCa between 1988 and 2003. Distant recurrences were separetely evaluated for the two studied cohort. Cox regression analyses evaluating the risk of developing distant recurrence after RC were built.
RESULTS: In the primary cohort composed by 1,081 patients 445 (41.2%) received a perioperative BT. The median follow up was 52 months (Interquartile range: 44-61 months). Overall, 277 (25.6%) patients incurred in distant recurrence during follow up period. In the second cohort composed by 433 patients treated at a single institution 183 (42.3%) patients received perioperative BT. The median follow up was 83 months (Interquartile range: 75-91 months). Distant recurrence during the follow up period were recorded in 127 (28.3%) patients. One, three and five-years distant recurrence rates were 81% vs. 85%, 65% vs. 70% and 60% vs. 68% for patients who received intraoperative vs. no BT transfusion (p¼0.03). One, three and five-years distant recurrence rates were 81% vs. 85%, 64% vs. 70% and 53% vs. 68% for patients who received postoperative vs. no BT transfusion (p¼0.4). Similar findings were observed in the validation studied cohort (all p ¼0.05). At multivariable analyses predicting distant recurrences, BT were not related to an increased risk to incur in distant recurrence (all p¼0.2) or different recurrence patterns in both studied cohorts.
CONCLUSIONS: BT administration in RC patients is not associated with different pattern or higher rates of distant recurrences when compared to patients who not received BT. New data are needed to investigate mechanisms behind the association between BT and survival in RC patients. . 197, No. 4S, Supplement, Sunday, May 14, 2017 
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